Clindamycin Topical
78 interactions 680 cited references
Also sold as:
C/T/S®
Cleocin-T®
Clinda-Derm®
Clindagel®
Clindets®
Evoclin®
About Clindamycin Topical
Topical clindamycin is used to treat acne. Clindamycin is in a class of medications called lincomycin antibiotics. It works by slowing or stopping the growth of bacteria that cause acne and by decreasing swelling. Read the full Clindamycin Topical drug information page →
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
· Updated Aug 9, 2026
· Editorial policy
· Data sources
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Clindamycin Topical Palbociclib Ibrance Increased exposure to CYP3A substrates with a narrow therapeutic index Details Clindamycin Topical Phenobarbital Fidoquel Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Clindamycin Topical Primidone Mysoline Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Clindamycin Topical Ranolazine Aspruzyo Increased exposure of CYP3A4 substrate Details Clindamycin Topical Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Clindamycin Topical Repotrectinib Augtyro Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Clindamycin Topical Ribociclib Kisqali Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Clindamycin Topical Selpercatinib Retevmo Increased substrate exposure and an increased risk for adverse effects Details Clindamycin Topical Sevabertinib Hyrnuo Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Clindamycin Topical Sotorasib Lumakras Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Clindamycin Topical Suzetrigine Journavx Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Clindamycin Topical Taurursodiol Decreased exposure of the CYP3A4 substrate Details Clindamycin Topical Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Clindamycin Topical Tocilizumab Actemra Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Clindamycin Topical Tovorafenib Ojemda Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Clindamycin Topical Treosulfan Grafapex Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse and serious life-threatening toxicit... Details Clindamycin Topical Tucatinib Tukysa Increased exposure to CYP3A substrate and risk of toxicity Details Clindamycin Topical Vonoprazan Voquezna Increased CYP3A substrates exposure Details Clindamycin Topical Vorasidenib Voranigo Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Clindamycin Topical Voriconazole Vfend Increased CYP3A4 substrates exposure and an increased efficacy of CYP3A4 substrates-related adverse effects DetailsModerate
Clindamycin Topical Artemether Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Clindamycin Topical Atracurium Enhanced and prolonged neuromuscular blockade Details Clindamycin Topical Cisatracurium Enhanced neuromuscular blocking action Details Clindamycin Topical Cyclosporine Atopica Decreased cycloSPORINE bioavailability Details Clindamycin Topical Doxacurium Enhanced and prolonged neuromuscular blockade Details Clindamycin Topical Gallamine Enhanced and prolonged neuromuscular blockade Details Clindamycin Topical Kaolin Pet Pectillin Decreased clindamycin effectiveness Details Clindamycin Topical Kratom Increased CYP3A substrate exposure Details Clindamycin Topical Lixisenatide Delayed therapeutic effect Details Clindamycin Topical Mavacamten Camzyos Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Clindamycin Topical Metocurine Enhanced and prolonged neuromuscular blockade Details Clindamycin Topical Mivacurium Enhanced and prolonged neuromuscular blockade Details Clindamycin Topical Pancuronium Pancuronium toxicity (respiratory depression) Details Clindamycin Topical Pipecuronium Enhanced and prolonged neuromuscular blockade Details Clindamycin Topical Rilzabrutinib Wayrilz Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Clindamycin Topical Rocuronium Enhanced and prolonged neuromuscular blockade Details Clindamycin Topical Tubocurarine Enhanced and prolonged neuromuscular blockade Details Clindamycin Topical Vecuronium Vecuronium toxicity (respiratory depression) DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacistEducational information only, not medical advice. Always confirm interactions with your pharmacist
or prescriber before making any change to your medications.